Thavaneswaran, Subotheni http://orcid.org/0000-0002-8946-6709
Lin, Frank http://orcid.org/0000-0001-9250-6874
Grady, John P.
Espinoza, David
Huang, Min Li
Chinchen, Sarah
Sebastian, Lucille
Kansara, Maya
Mersiades, Tony
Lee, Chee Khoon
Desai, Jayesh http://orcid.org/0000-0003-4246-9344
Grimison, Peter
Brown, Michael
Millward, Michael
Harrup, Rosemary
O’Byrne, Ken
Nagrial, Adnan
Craft, Paul
Simes, John http://orcid.org/0000-0002-3740-7563
Joshua, Anthony M.
Thomas, David M.
Funding for this research was provided by:
Australian Institute of Health and Welfare, Australian Government
Article History
Received: 18 March 2024
Accepted: 29 August 2024
First Online: 9 September 2024
Competing interests
: D.M.T. as CEO of Omico, a non-profit organisation has received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene, Elevation Oncology, RedX Pharmaceuticals, Sun-Pharma, Bayer, Abbvie, George Clinical, Janssen, Merck, Kinnate, Microba, BioTessellate, Australian Unity, Foundation Medicine, Guardant, Intervenn, Amgen, Seattle Genetics and Eli Lilly. D.M.T. also serves on the advisory boards or committees for Canteen, UNSW SPHERE and NSW government in respect to genomics and translational medicine.